Abstract
Endoscopic ultrasound (EUS) has been proven to be the most accurate staging modality for esophageal cancer (EsoCa). However, the ability of EUS to predict outcomes or prognosis is unclear.We prospectively followed patients who had EUS for EsoCa staging to determine if EUS can predict survival in EsoCa. Methods: 204 consecutive patients undergoing EUS for EsoCa staging were studied over a 66 month (mo.) period. Survival data was determined in 196 patients. Median survival was calculated for each T-stage and N-stage as determined by EUS. Kaplan Meier survival curves were generated for each stage and Cox regression was used to test for statistically significant differences in survival adjusting for age, sex, and histology (adeno CA vs. squamous cell CA). The differences in survival in T stage and N stage were adjusted for N stage and T stage respectively. Results: The incidence of each T and N stage was Tis (7), T1 (24), T2 (47), T3 (93), T4(28), Tx (5) and N0 (53), N1 (145), Nx (6). Median follow-up after EUS exam was 35.4 mos. ranging from 12 to 66 mos. Median survival in mos. for each stage was Tis (26.7), T1 (21.6), T2 (19.5), T3 (15.6), T4 (6.5) and N0 (25.0), N1 (13.5). Overall there was a significant difference in the ability of EUS determined T stage to predict survival (p=0.001), with patients having higher EUS T stages succumbing sooner. This difference remained significant after adjusting for age, sex, and histology (P=.035). Patients with local disease (Tis, T1, T2) determined by EUS live significantly longer when compared with patients with advanced disease (T3, T4) (HR=2.0, 95%CI 1.34-2.95). Patients with EUS N stage 0 had significantly longer survival than patients with EUS N stage 1 [25.0 mos. vs. 13.5 mos.] (p
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call